Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;2(4):753-61.
doi: 10.2147/btt.s3197.

Therapeutic vaccines for malignant brain tumors

Michael P Gustafson  1 , Keith L Knutson, Allan B Dietz
Affiliations

Therapeutic vaccines for malignant brain tumors

Michael P Gustafson et al. Biologics. 2008 Dec.

Abstract

Malignant gliomas are the most common and aggressive form of brain tumors. Current therapy consists of surgical resection, followed by radiation therapy and concomitant chemotherapy. Despite these treatments, the prognosis for patients is poor. As such, investigative therapies including tumor vaccines have targeted this devastating condition. Recent clinical trials involving immunotherapy, specifically dendritic cell (DC) based vaccines, have shown promising results. Overall, these vaccines are well tolerated with few documented side effects. In many patients receiving vaccines, tumor progression was delayed and the median overall survival of these patients was prolonged. Despite these encouraging results, several factors have limited the efficacy of DC vaccines. Here we discuss the potential of DC vaccines as adjuvant therapy and current obstacles of generating highly pure and potent DC vaccines in the context of malignant glioma. Taken together, the results from earlier clinical studies justify additional clinical trials aimed at improving the efficacy of DC vaccines.

Keywords: dendritic cells; glioblastoma multiforme; immunotherapy; malignant glioma; vaccine.

PubMed Disclaimer

References

    1. Aerts-Toegaert C, Heirman C, et al. CD83 expression on dendritic cells and T cells:Correlation with effective immune responses. Eur J Immunol. 2007;37:686–95. - PubMed
    1. Bax M, García-Vallejo JJ, et al. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J Immunol. 2007;179:8216–24. - PubMed
    1. Biernacki K, Prat A, et al. Regulation of cellular and molecular trafficking across human brain endothelial cells by Th1- and Th2-polarized lymphocytes. J Neuropathol Exp Neurol. 2004;63:223–32. - PubMed
    1. Bonifaz LC, Bonnyay DP, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199:815–24. - PMC - PubMed
    1. Britten CM, Janetzki S, et al. Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol Immunother. 2008;57:285–8. - PMC - PubMed